Skip to main content
Premium Trial:

Request an Annual Quote

PacBio Inks Agreement to Sell up to $30M of its Shares

NEW YORK (GenomeWeb News) – Pacific Biosciences said after the close of the market on Friday that it has signed an agreement with Cantor Fitzgerald to offer and sell up to $30 million in shares of its common stock.

In a document filed with the US Securities and Exchange Commission, PacBio said that its shares will be sold through Cantor. The Menlo Park, Calif.-based next-generation sequencing instrument maker added that it intends to use proceeds from the offering for general corporate purposes, including capital expenditures and working capital, as well as for acquisitions of other businesses and IP.

PacBio is not required to sell any shares under the agreement and will pay Cantor a commission of 3 percent of the gross sales price per share sold. It is paying Cantor's legal fees and a disbursement up to $50,000 in the aggregate in connection with the agreement.

In its second-quarter earnings release in July, PacBio said it had $137.1 million in cash and investments.

The Scan

Booster for Kids

The US Food and Drug Administration has authorized a booster dose of Pfizer-BioNTech's SARS-CoV-2 vaccine for 5-to-11-year olds, the Washington Post reports.

Novavax Anticipates Authorization

Novavax expects to receive US Food and Drug Administration authorization for vaccine soon, according to CNBC.

Some Old Microbes Indeed

Vice reports that researchers may have uncovered 830-million-year-old microbes.

PNAS Papers on Meiotic Crossover, RNA Targeting, SNAT7 mTORC1 Regulation

In PNAS this week: meiotic crossover formation in C. elegans, approach to identify small molecules affecting RNA activity, and more.